Skip to main content

Drug Active in ‘Undruggable’ KRAS-Mutant NSCLC

*September 2020*

A small-molecule inhibitor targeting a KRAS mutation achieved a high rate of disease control in a preliminary study of patients with non-small cell lung cancer (NSCLC).

A third of patients with NSCLC had objective responses with sotorasib, and 88.1% attained disease control. The disease control rate (DCR) surpassed 90% in the subgroup of patients who received the recommended phase II dose of the drug.

No dose-limiting toxicity was observed, and grade 3/4 treatment-related adverse events (TRAEs) were manageable in most cases, reported David Hong, MD, of the University of Texas MD Anderson Cancer Center in Houston. Read more.